185 related articles for article (PubMed ID: 34282593)
21. [Dopamine-agonist resistant prolactinomas: diagnosis and management].
Musolino NR; Passos VQ
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):641-50. PubMed ID: 16444347
[TBL] [Abstract][Full Text] [Related]
22. Pasireotide: A potential therapeutic alternative for resistant prolactinoma.
Lasolle H; Vasiljevic A; Borson-Chazot F; Raverot G
Ann Endocrinol (Paris); 2019 Apr; 80(2):84-88. PubMed ID: 30318256
[TBL] [Abstract][Full Text] [Related]
23. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
[TBL] [Abstract][Full Text] [Related]
24. Update on prolactinomas. Part 2: Treatment and management strategies.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
[TBL] [Abstract][Full Text] [Related]
25. Resistant prolactinomas.
Vasilev V; Daly AF; Vroonen L; Zacharieva S; Beckers A
J Endocrinol Invest; 2011 Apr; 34(4):312-6. PubMed ID: 21406957
[TBL] [Abstract][Full Text] [Related]
26. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of multimodal therapy for giant prolactinomas.
Andujar-Plata P; Villar-Taibo R; Ballesteros-Pomar MD; Vidal-Casariego A; Pérez-Corral B; Cabezas-Agrícola JM; Álvarez-Vázquez P; Serramito R; Bernabeu I
Endocrine; 2017 Jan; 55(1):231-238. PubMed ID: 27704480
[TBL] [Abstract][Full Text] [Related]
28. Giant Prolactinomas.
Shimon I
Neuroendocrinology; 2019; 109(1):51-56. PubMed ID: 30404098
[TBL] [Abstract][Full Text] [Related]
29. Current and Perspective Approaches to the Treatment of Prolactinomas.
Tykhonova T; Barabash N; Kanishcheva O
Acta Med Litu; 2023; 30(2):96-107. PubMed ID: 38516518
[TBL] [Abstract][Full Text] [Related]
30. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
[TBL] [Abstract][Full Text] [Related]
31. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
32. Management of medically refractory prolactinoma.
Molitch ME
J Neurooncol; 2014 May; 117(3):421-8. PubMed ID: 24146188
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
[TBL] [Abstract][Full Text] [Related]
34. HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.
Fukuoka H; Cooper O; Mizutani J; Tong Y; Ren SG; Bannykh S; Melmed S
Mol Endocrinol; 2011 Jan; 25(1):92-103. PubMed ID: 21106881
[TBL] [Abstract][Full Text] [Related]
35. Prolactinomas in males: any differences?
Duskin-Bitan H; Shimon I
Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
[TBL] [Abstract][Full Text] [Related]
36. Management of resistant prolactinomas.
Olafsdottir A; Schlechte J
Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
[TBL] [Abstract][Full Text] [Related]
37. Prolactinomas.
Glezer A; Bronstein MD
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):71-8. PubMed ID: 25732643
[TBL] [Abstract][Full Text] [Related]
38. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
39. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
Cuny T; Mohamed A; Graillon T; Roche C; Defilles C; Germanetti AL; Couderc B; Figarella-Branger D; Enjalbert A; Barlier A; Saveanu A
Mol Cell Endocrinol; 2012 May; 355(1):106-13. PubMed ID: 22348806
[TBL] [Abstract][Full Text] [Related]
40. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.
Cooper O; Bonert VS; Rudnick J; Pressman BD; Lo J; Salvatori R; Yuen KCJ; Fleseriu M; Melmed S
J Clin Endocrinol Metab; 2021 Jan; 106(2):e917-e925. PubMed ID: 33150390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]